Cordavis

Vermont New Product Launch Report

NDC	DRUG PROD DESC	INTRODUCED TO MARKET DATE
83457-0107-01	Hyrimoz® (adalimuab-adcz) 80 mg/0.8 mL Prefilled Pen	2/1/2024
83457-0108-01	Hyrimoz® (adalimuab-adcz) 20 mg/0.2 mL Prefilled Syringe	2/1/2024

83457-0112-01	Hyrimoz® (adalimuab-adcz) Starter Pack 80 mg/0.8 ml-40 mg/0.4 mL Prefilled Pen	2/1/2024
83457-0113-01	Hyrimoz® (adalimuab-adcz) 80 mg/0.8 mL Prefilled Pen	2/1/2024
10 or 11 Digit NDC	This will include: Drug Trade Name, Active Ingredient, Strength, and Size	Date Product was commercially available

Key	**Used for Full Report Due 30 Days After Initial Notice**
Submissions Made To	AGO.highcostprescriptiondrugs@vermont.gov

WAC AT INTRODUCTION	MARKETING PRICING PLAN	MARKETING PRICING NONPUBLIC
$ 2,600.00	Cordavis Hyrimoz has being developed as a co-manufacturing biosimilar initiative. Hyrimoz exists on the market to-day under other manufaturer NDCs. There is currently no specific marketing and/or advertising budget or plan associated with this NDC. Cordavis is introducing the Hyrimoz NDC to create compention in the Biosimilar market and help drive down the overall cost of drugs. Cordavis Hyrimoz pricing strategy was to bring a Biosimilar to market at a price point that was at least 80% below the list price of the brand equivalent.	N
$ 1,300.00	Cordavis Hyrimoz has being developed as a co-manufacturing biosimilar initiative. Hyrimoz exists on the market to-day under other manufaturer NDCs. There is currently no specific marketing and/or advertising budget or plan associated with this NDC. Cordavis is introducing the Hyrimoz NDC to create compention in the Biosimilar market and help drive down the overall cost of drugs. Cordavis Hyrimoz pricing strategy was to bring a Biosimilar to market at a price point that was at least 80% below the list price of the brand equivalent.	N

$ 2,600.00	Cordavis Hyrimoz has being developed as a co-manufacturing biosimilar initiative. Hyrimoz exists on the market to-day under other manufaturer NDCs. There is currently no specific marketing and/or advertising budget or plan associated with this NDC. Cordavis is introducing the Hyrimoz NDC to create compention in the Biosimilar market and help drive down the overall cost of drugs. Cordavis Hyrimoz pricing strategy was to bring a Biosimilar to market at a price point that was at least 80% below the list price of the brand equivalent.	N
$ 3,900.00	Cordavis Hyrimoz has being developed as a co-manufacturing biosimilar initiative. Hyrimoz exists on the market to-day under other manufaturer NDCs. There is currently no specific marketing and/or advertising budget or plan associated with this NDC. Cordavis is introducing the Hyrimoz NDC to create compention in the Biosimilar market and help drive down the overall cost of drugs. Cordavis Hyrimoz pricing strategy was to bring a Biosimilar to market at a price point that was at least 80% below the list price of the brand equivalent.	N
WAC on the date the Product was commercially available	A narrative description of the marketing and pricing plans used in the launch of the new prescription drug in the United States and internationally	Please respond with Yes or No

ESTIMATED PATIENTS	BREAKTHROUGH THERAPY INDICATOR	PRIORITY REVIEW INDICATOR
2315	N	N
559	N	N

215	N	N
562	N	N
The estimated number of patients in the United States with a condition for which the new prescription drug may be prescribed	Indicate whether the drug was granted breakthrough therapy designation or priority review by the federal Food and Drug Administration prior to approval	Indicate whether the drug was granted breakthrough therapy designation or priority review by the federal Food and Drug Administration prior to approval

ACQUISITION DATE	ACQUISITION PRICE	ACQUISITION PRICE NONPUBLIC
[redacted]		



If this field in N/A then please leave blank	If this field in N/A then please leave blank	Please respond with Yes or No

ACQUISITION PRICE COMMENT	GENERAL COMMENTS
[redacted]	

If this field in N/A then please leave blank